EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

EGFR-driven non-small-cell lung cancer (NSCLC) patients are currently treated with TKIs targeting EGFR, such as erlotinib or osimertinib. Despite a promising initial response to TKI treatment, most patients gain resistance to oncogene-targeted therapy, and tumours progress. With the development of i...

Full description

Bibliographic Details
Main Authors: Carolin Selenz, Anik Compes, Marieke Nill, Sven Borchmann, Margarete Odenthal, Alexandra Florin, Johannes Brägelmann, Reinhard Büttner, Lydia Meder, Roland T. Ullrich
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
NSCLC
EGFR
tyrosine kinase inhibitors
immune checkpoint blockade
anti-PD-1
erlotinib
Online Access:https://www.mdpi.com/2072-6694/14/16/3943

Internet

https://www.mdpi.com/2072-6694/14/16/3943

Similar Items